Segment Information

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

We operate in one business segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. All products are included in one segment, because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. Total product sales on an individual product basis are summarized in the following table (in millions):

	Three Months Ended
	March 31,
	2015		2014
Antiviral products:
Harvoni	$	3,579	$	—
Sovaldi	972		2,274
Truvada	771		760
Atripla	734		780
Stribild	356		215
Complera/Eviplera	320		251
Viread	234		211
Other antiviral	22		18
Total antiviral products	6,988		4,509
Other products:
Letairis	151		123
Ranexa	117		111
AmBisome	85		92
Zydelig	26		—
Other	38		36
Total product sales	$	7,405	$	4,871

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):

	Three Months Ended
	March 31,
	2015		2014
McKesson Corp.	25	%	23	%
AmerisourceBergen Corp.	21	%	27	%
Cardinal Health, Inc.	17	%	13	%